Kishi K, Kanai T, Sakon M, Fujiwara Y, Takeda Y, Higaki N, Yamada T, Taniguchi K, Hasuike Y, Gotoh M
Dept. of Surgery II, Osaka University Medical School.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1590-3.
We devised a new therapeutic modality for multiple hepatocellular carcinoma (HCC) consisting of transarterial immuno-embolization (TIE) using OK-432 and fibrinogen, and applied the treatment to 22 patients with advanced HCC who had been insensitive to TAE, and 21 patients who had no treatment. Nineteen patients had a high AFP level of more than 200 ng/ml. The serum AFP level decreased in 15 patients after TIE, and in 7 patients the AFP level decreased to less than 30%. Furthermore, a marked reduction in tumor size was observed in 69% after TIE. We report 61% 1-year, and 3-year survival rate for cases who had been insensitive to TAE, and 86% 2-year survival rate for those who selected TIE as the first choice. A high fever of more than 38 degrees C occurred in all cases, and hypotension less than 80 mmHg was observed in 42% patients. No deterioration of liver function and no disturbance of the coagulation-fibrinolysis system due to TIE except in one patient with liver failure after TIE.
我们设计了一种针对多发性肝细胞癌（HCC）的新治疗方法，即使用OK-432和纤维蛋白原进行经动脉免疫栓塞（TIE），并将该治疗应用于22例对经动脉栓塞化疗（TAE）不敏感的晚期HCC患者以及21例未接受过治疗的患者。19例患者甲胎蛋白（AFP）水平高于200 ng/ml。TIE治疗后，15例患者血清AFP水平下降，7例患者AFP水平下降至30%以下。此外，TIE治疗后69%的患者肿瘤大小显著缩小。我们报告了对TAE不敏感的患者1年生存率为61%，3年生存率为61%；而将TIE作为首选治疗的患者2年生存率为86%。所有患者均出现体温高于38摄氏度的高热，42%的患者出现血压低于80 mmHg的低血压。除1例TIE治疗后出现肝功能衰竭的患者外，TIE未导致肝功能恶化及凝血-纤溶系统紊乱。
